

# Review of: "Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group"

Jing Zhao<sup>1</sup>

<sup>1</sup> Sun Yat-Sen University

Potential competing interests: No potential competing interests to declare.

From a clinical practice perspective, the study expounds the personal application of antiresorptive drugs in cancer patients with bone metastasis by raising clinical questions and based on PICO principle. This is a very wonderful and creative job for clinical practice. But I have some concerns about this study.

1. In the **“COST OF THE DRUG”**, the study only describes the cost differences between different therapeutic approach, and there is no direct comparison or statistical comparison of the cost differences between the personalized treatment and “one-fit-for-all” therapy.

2. In the **“RENAL TOXICITY”** and **“HYPOCALCAEMIA”**, the study did not list the specific indicators of renal function and hypocalcaemia, and did not make statistical comparison between different therapeutic approaches. Is there any evidence that “In these cases, denosumab is preferred”?

In addition, there are some minor writing problems in this manuscript:

1. In figure 2, the format euro is different and needs to be correct and uniform such as € 50 and € 12.75.
2. In the first sentence of “Results”, the “Stud Group” should be corrected to the “Study Group”.